Financial News

Nicox to Present at the Glaucoma 360 New Horizons Forum

Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Tomas Navratil, PhD, Executive Vice President, Head of Development, will present at the Glaucoma 360 New Horizons Forum hosted by the Glaucoma Research Foundation on February 1st, 2019 at 1:22 PM PST. Dr. Navratil will present in the session…

Read more

Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatment of the eyelid margin for patients with acute exacerbations of blepharitis.

Read more

Nicox Establishes High-Profile Glaucoma Clinical Advisory Board

  • Key U.S. clinical investigators and opinion leaders to support and guide the development of Nicox’s innovative NO-donating therapeutics including NCX 470 currently in a U.S. Phase 2 clinical study

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the formation of Nicox Glaucoma Clinical Advisory Board,

Read more
More news
Press releases
More press releases